
Amgen AMGN.O shares down 0.8% to $342 ahead of Q4 results due after the closing bell
Shares in obesity drugmakers declined on Tuersday after Novo Nordisk NOVOb.CO forecast a sharper than expected sales decline for 2026
Q4 adj. EPS expected at $4.73 on a 4.2% increase in revenue to $9.47 bln, per LSEG data, vs yr-ago results EPS of $4.73
The drugmaker has met or beaten EPS estimates in seven of past eight qtrs, with most recent miss in Q2 2024
Of the 35 analysts that cover Amgen Inc, the breakdown of recommendations are 17 "strong buy" or "buy," 15 "hold" and 3 "sell" or "strong sell" ratings
Median price target of $335 is up from $327.50 a month ago
AMGN shares up 4.2% YTD stock performance vs 1.7% gain in Dow Industrials .DJI